Insmed Inc (FRA:IM8N)
€ 66.5 -1 (-1.52%) Market Cap: 11.45 Bil Enterprise Value: 11.43 Bil PE Ratio: 0 PB Ratio: 308.84 GF Score: 61/100

Insmed Inc to Discuss Topline Data from TPIP Phase 1 Study Conference Call Transcript

Feb 19, 2021 / 01:30PM GMT
Release Date Price: €33.2 (-5.14%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Insmed TPIP's Phase I Data Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Eleanor Barisser. Thank you. Please go ahead.

Eleanor Barisser
Insmed Incorporated - Associate Director of IR

Thank you, Megan. Good morning, and welcome to today's conference call to discuss our Phase I top line results for Treprostinil Palmitil Inhalation Powder.

Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, which are available through the SEC's website at www.sec.gov or from our website for information concerning the risk factors that could affect the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot